"Diamond" over-coated Microstrip Gas Chambers for high rate operation

We describe the recent developments on the diamond-like carbon (DLC) over-coated Microstrip Gas Chambers made on drawn glass substrates. MSGC surface coating with thin DLC layer of stable and controlled resistivity was proposed to overcome the limitation of detector operation due to surface charging-up under avalanches. This brings also advantages for the detector manufacturing technology. The thin layer, deposited on top of a manufactured MSGC (over-coating), demonstrates excellent mechanical properties and very good stability. We report on recent measurements with DLC over-coated MSGCs of various surface resistivities (ranging from 1013W/r to 1016W/r) on D-263 and AF45 glass substrates. Over-coated MSGCs exhibit good rate capability for the resistivity of the surface around 1015W/r. Stable operation up to 50 mC/cm of accumulated charge from avalanches has been demonstrated

Operation of microstrip gas chambers manufactured on glass coated with high resistivity diamond-like layers

We describe recent observations and measurements realized with micro-strip gas chambers (MSGCs) manufactured on boro-silicate glass coated with a thin layer of diamond-like carbon (DLC) having a surface resistivity around 4.10$^{16}\Omega/\Box$. The role of the back-pla electrode configuration and potential in the detector performance has been studied. Even for this very high resistivity of the coatings, MSGCs operate differently from those manufactured on bare boro-silicate glass; the charge gain increases with the radiation flux for counting rates above 103 Hz/mm2, reaching a value 60% higher for 105 Hz/mm2. This behavior does not depend on the presence and potential of the back plane electrode; however, both maximum gain and rate capability are influenced by the drift field. From this study, compared with measurements realized previously with other detectors, we deduce that for stable high rate operation of MSGCs the resistivity of the coating should not exceed ~10$^{15}\Omega/\Box$

Optimization of design and beam test of microstrip gas chambers

We describe recent experimental and theoretical work aimed at optimizing the geometry and the operation of micro-strip gas chambers in order to improve their performance and reliability. With the help of a simulation program, we have studied the mechanism of signal propagation and analyzed the effects on signal shape and size of resistivity of strips, grouping of biased strips and presence of a back-plane. Several detectors manufactured according to the results of the study and equipped with fast amplifiers have been installed in a test beam to study general operating characteristics, efficiency and localization accuracy; preliminary results of the data analysis are discussed

Study of ageing and gain limits of microstrip gas chambers at high rates

The CMS experiment comprises MSGCs as one of the key detection elements for high luminosity tracking at LHC. In addition to the high dose rate of 10 mC/year per cm of strip, these detectors have to survive the hostile presence of highly ionizing particles, neutrons low energy gammas and hadrons. In this report we present the results of systematic tests on maximum safe operational gain limits in MSGCs before the discharge. Long term ageing tests performed on prototype open Ibanana¹ modules envisaged to be arranged around the interaction region in the forward part of the CMS tracker show no evidence of gain drop up to equivalent ~ 10 years of LHC operation. A comparison is made between argon and neon gas mixtures with DME in equal proportions by investigating long term irradiation effects on chamber operation by introducing controlled and reproducible pollution in the gas lines

PetIGA: A framework for high-performance isogeometric analysis

We present PetIGA, a code framework to approximate the solution of partial differential equations using isogeometric analysis. PetIGA can be used to assemble matrices and vectors which come from a Galerkin weak form, discretized with Non-Uniform Rational B-spline basis functions. We base our framework on PETSc, a high-performance library for the scalable solution of partial differential equations, which simplifies the development of large-scale scientific codes, provides a rich environment for prototyping, and separates parallelism from algorithm choice. We describe the implementation of PetIGA, and exemplify its use by solving a model nonlinear problem. To illustrate the robustness and flexibility of PetIGA, we solve some challenging nonlinear partial differential equations that include problems in both solid and fluid mechanics. We show strong scaling results on up to 4096 cores, which confirm the suitability of PetIGA for large scale simulations

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes):

BACKGROUND: The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group--Bone Tumor Study Group (GSF-GETO) national registry. METHODS: All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed. RESULTS: Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs. The median age at the beginning of treatment was 19 years (range 9-72). The median number of previous lines of chemotherapy was 3 (range 1-8). Before inclusion, 3 patients were in second complete remission, 26 were in progression for metastatic relapse. Twenty-three patients received sirolimus (in combination with cyclophosphamide for 18); 5, sunitinib; 4, sorafenib; and one, pazopanib. Stable disease was observed for 45.5% of patients (95% Confidence Interval (CI) [20-52.8]). The median Progression-Free Survival (PFS) was 3 months (95% CI [2-5.4]) for patients treated by sirolimus and 1.8 months (95% CI [1.3-2.8]) for patients receiving multi-targeted tyrosine kinase inhibitors; 6-month PFS 15%. The median Overall Survival (OS) was 6.8 months (95% CI [4.7-12.1]), and one-year OS was 24%. In a multivariate analysis, PFS was superior for patients receiving sirolimus compared to other TTs (Hazard Ratio (HR) = 2.7, 95% CI [1.05-7.1]). No toxic death was reported. Grade 3 and 4 toxicities were observed in 27 and 6% of cases respectively. CONCLUSION: Off-label TTs, especially sirolimus, reported benefit in the treatment of refractory osteosarcomas with an acceptable toxicity profile, including in pediatric population